Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
AbbVie will pay I-Mab $180 million for access outside China to lemzoparlimab, an anti-CD47 antibody in development for several types of cancer. Many cancer cells display CD47 on their surfaces to evade detection by white blood cells called macrophages. CD47 has long been a target of interest to cancer-drug developers, but inhibitors can cause anemia—a side effect that I-Mab claims lemzoparlimab avoids. AbbVie paid the Chinese firm another $20 million because of positive Phase I results for the antibody.
This article has been sent to the following recipient: